Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study - Wikidata - wikimedia - TriplyDB

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

http://www.wikidata.org/entity/Q33990959

about

Brainstem Glioma in Adults DIPG in Children - What Can We Learn from the Past?Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models Permeability imaging in pediatric brain tumors.Opportunities and challenges for successful use of bevacizumab in pediatrics.Adult brainstem gliomas Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: a case report.Bevacizumab for acute neurologic deterioration in patients with glioblastoma.Advances in the management of paediatric high-grade glioma.Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.A pilot study of bevacizumab-based therapy in patients with newly diagnosed high-grade gliomas and diffuse intrinsic pontine gliomas.Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.Children's Oncology Group's 2013 blueprint for research: central nervous system tumors.Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters.Management of diffuse pontine gliomas in children: recent developments.The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma.Brainstem glioma: a review.A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.Management of high-grade gliomas in the pediatric patient: Past, present, and future.Effect of time from diagnosis to start of radiotherapy on children with diffuse intrinsic pontine glioma Challenging issues in pediatric oncology Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumors Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study.Diffuse intrinsic pontine glioma: poised for progress.Advances in paediatric cancer treatment The VEGF pathway in cancer and disease: responses, resistance, and the path forward.Immunotherapy in pediatric malignancies: current status and future perspectives Neurotoxicity of biologically targeted agents in pediatric cancer trials Biologically targeted therapeutics in pediatric brain tumors.Bevacizumab for the treatment of glioblastoma.The rationale for targeted therapies in medulloblastoma.Characterization of the blood brain barrier in pediatric central nervous system neoplasms.Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.

P2860

Q26739232-71B44482-EE0A-4B90-BF44-1CEC1CA4A4C2 Q26777843-618161A1-EDC1-4025-A1BF-5F28C0830E6C Q26785952-409C9829-503C-4766-851D-A9757B1A280E Q27345024-5EAF88ED-A75B-43AF-9BA0-01CEE9F66BA9 Q30392559-F5D91AF0-94BA-4ABA-B14F-18AD55D2CF24 Q30454883-1E98ABB0-974D-45F2-A228-AA4C32D3B561 Q30457821-A1DA8BF3-8716-487C-9E79-BC9DC6316303 Q30616602-2D5BB87E-9540-4B02-ACB8-F5BBEAD35535 Q30679553-F1D787AF-6530-4532-A937-FF9494EC868D Q30838127-BA680AF7-87F9-4786-81A3-80AEAD7BAAF4 Q30870633-92ABA3C1-E715-426E-AB9D-4424BEEDA932 Q33416917-284404EC-E420-4849-9B2D-B00DF91A84C1 Q33428049-F07BC310-5BDD-4368-8E8D-D124526D12FA Q33438641-738C3A95-1034-43BA-9A1E-D6B2DC559C83 Q34285237-A95D0395-F3C7-47BB-819E-9A5025F2D26A Q34286305-B325CEDE-9D00-4F0B-A482-030F2B512DF4 Q34347540-6650E508-88AB-4D93-9F82-CA81BDEDC688 Q34468816-2CC048BF-D5B3-4133-A253-9D22E12A80B2 Q34628180-97B00AA0-5DD1-43C2-9113-CF9DC71188FB Q34872658-0A04EE93-07CF-4179-BC17-3DAAB5D4B6A2 Q35021664-57C00175-4DA4-428D-B471-8B849E7B2940 Q35090526-EEE6E452-F5BD-44BF-8A63-47F3E11D4EAF Q35206259-BBBB0EA3-E8B0-4E03-A60A-B07CFA79ACC6 Q35230772-4E3CCACD-24F9-4CE7-866D-C5B447532303 Q35602419-E86C2900-FF8B-4E40-BFE1-2B08E965DC06 Q35667216-0E3C0762-6E4F-4774-B7B9-8481236F0D44 Q35826030-A0425003-9C60-4A1A-885F-60A4E8163695 Q36031619-4B693196-ABD9-486F-B1C7-5C9C3D7A7F2B Q36344746-1BFA3C28-C5AB-4D20-B0AC-309F0C7C93F7 Q36492719-65CCF05B-D551-4D37-9693-89133B17886D Q36508630-CC98556E-D884-4A8B-AFF9-9538A0A898F8 Q36526512-6C5FAD1D-5125-4DC6-8DD6-1D0FF43D7516 Q36691818-0B6C7C48-4F8B-4F57-8CFA-AE52495B3114 Q36766221-CCC9DBAD-0C6C-42FD-9555-23D106C3A127 Q36844744-EFFDCB86-C8E4-4031-AB40-FE9807AD0EEC Q36929502-4D03F34A-9291-4F0E-AC96-FAD09BD4B012 Q37409736-6D86D5C6-A0AD-4137-AE37-B8FA8C183A81 Q37462324-ECA2AE10-7B13-4169-B775-15DEB88A83C9 Q37484213-3705D522-9DC8-4A5E-A28F-F765AEDE8BE7 Q37492128-C1E2C544-D89D-4F59-85FD-DB56EC84343D

P2860

Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study

http://www.wikidata.org/entity/Q33990959

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study

@ast

Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study

@en

type

label

Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study

@ast

Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study

@en

prefLabel

Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study

@ast

Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study

@en

P1433

Q33990959-227AFB55-A0F6-44D4-B8C2-E8B338F15B35

P1476

Q33990959-FEBFC385-139A-4FAD-8133-8DA414A8373C

P2093

Q33990959-02035FB0-D61F-4D7D-BC4B-CFB4FC50AF9C

Q33990959-1B3FAD5E-9319-451D-8CDB-0385C9335959

Q33990959-201CFD0E-E594-462F-BAA1-71C8BA44593B

Q33990959-4EC91D8A-A53D-4EC0-89FE-4DCB39AD9357

Q33990959-6DC33C15-BF6B-4D82-A6C0-5D313CFC20C7

Q33990959-860FCD70-E562-4854-8454-8F9EFDF280C9

Q33990959-99282690-3BA4-4B16-B476-D7F8C07DE9FE

Q33990959-B2AFAF51-7A2F-4B9D-8E0A-64CF17AF1091

Q33990959-E991A178-8EE5-4024-B9D6-B059437DDBC7

P2860

Q33990959-0B8C24A4-1633-4446-9550-0C429078AF30

Q33990959-0DB8C038-D343-420F-B76D-6611C34AE931

Q33990959-1BD4CC39-CE0A-46CF-B929-4B62536C249A

Q33990959-25EB9B18-8DA4-466F-B3BE-BCF17B03A3C9

Q33990959-27CA0CFD-CDDD-4D11-BF4F-28C8C55C0456

Q33990959-3A307705-618C-4102-981B-1E35871EAC39

Q33990959-6631F462-A5B3-4B49-BD34-FB122AA586A4

Q33990959-68ECD994-53B2-470C-9CA8-DD9F59658FCA

Q33990959-71D579E3-56D1-41BC-9093-A8D649CAD410

Q33990959-77A49DE7-BD5C-422D-BDC3-7095C6DE82B6

P304

Q33990959-B9631EF3-76D8-45AC-AEDC-DD37938EAEC0

P31

Q33990959-7ABE5730-46ED-4DBA-8DD6-B35F0D75B2C0

P356

Q33990959-C12D5B0D-B111-47B5-8B55-8344C0538A80

P407

Q33990959-8CBDDCF6-EF7F-4DE1-8799-01CE9BB7C410

P433

Q33990959-3AA6EDF0-3D1A-4EA4-BD9B-09C0123B2677

P478

Q33990959-0DE2DD56-D690-4174-AAC0-FCEB3C462BAA

P50

Q33990959-644187F3-6EBC-4C3C-B0A8-2A2382B6A36D

Q33990959-A20C9931-8CAE-454A-A92B-2D8C56D6A14A

P577

Q33990959-DF46DAC8-C418-41BA-883C-86674A6A29B2

P698

Q33990959-A7CFCAC9-4EF2-4F93-8944-6167F056FC79

P921

Q33990959-6AA19E65-EF19-4393-B096-DDFD5D161371

P932

Q33990959-0F97F1F7-A89F-452D-B1CD-A1034C9D2BE5

P356

JCO.2009.26.8789

P1433

Journal of Clinical Oncology

P1476

Lack of efficacy of bevacizuma ...... c Brain Tumor Consortium study

@en

P2093

Arzu Onar-Thomas

http://www.w3.org/2001/XMLSchema#string

Brian N Rood

http://www.w3.org/2001/XMLSchema#string

James M Boyett

http://www.w3.org/2001/XMLSchema#string

Larry E Kun

http://www.w3.org/2001/XMLSchema#string

Richard J Gilbertson

http://www.w3.org/2001/XMLSchema#string

Roger J Packer

http://www.w3.org/2001/XMLSchema#string

Sridhar Vajapeyam

http://www.w3.org/2001/XMLSchema#string

Susan N Chi

http://www.w3.org/2001/XMLSchema#string

Tina Young Poussaint

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor angiogenesis: therapeutic implications

Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer

A perivascular niche for brain tumor stem cells

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

What is the evidence that tumors are angiogenesis dependent?

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Monitoring cytotoxic tumour treatment response by diffusion magnetic resonance imaging and proton spectroscopy.

Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study.

Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.

P304

3069-3075

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2009.26.8789

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

Henry Seth Friedman

Sridharan Gururangan

P577

2010-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20479404

http://www.w3.org/2001/XMLSchema#string

P921

P932

2903337

http://www.w3.org/2001/XMLSchema#string